Improving vaccine efficacy against malignant glioma

Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L. Lauing; Rishi R. Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J. Raizer; David C. Binder; C. David James; Derek A. Wainwright

doi:10.1080/2162402X.2016.1196311

Improving vaccine efficacy against malignant glioma

Erik Ladomersky, Matthew Genet, Lijie Zhai, Galina Gritsina, Kristen L. Lauing, Rishi R. Lulla, Jason Fangusaro, Alicia Lenzen, Priya Kumthekar, Jeffrey J. Raizer, David C. Binder, C. David James, Derek A. Wainwright^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

Original language	English (US)
Article number	e1196311
Journal	OncoImmunology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1080/2162402X.2016.1196311
State	Published - Aug 2 2016

Keywords

Cancer immunity
Dendritic cell vaccine
HSPPC-96
Immunosuppression
Rindopepimut
cancer vaccines
glioma
pediatric glioma

ASJC Scopus subject areas

Oncology
Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402X.2016.1196311

Cite this

@article{08386efb860340f199b36180a6ecfe4c,

title = "Improving vaccine efficacy against malignant glioma",

abstract = "The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.",

keywords = "Cancer immunity, Dendritic cell vaccine, HSPPC-96, Immunosuppression, Rindopepimut, cancer vaccines, glioma, pediatric glioma",

author = "Erik Ladomersky and Matthew Genet and Lijie Zhai and Galina Gritsina and Lauing, {Kristen L.} and Lulla, {Rishi R.} and Jason Fangusaro and Alicia Lenzen and Priya Kumthekar and Raizer, {Jeffrey J.} and Binder, {David C.} and James, {C. David} and Wainwright, {Derek A.}",

note = "Publisher Copyright: {\textcopyright} 2016 Taylor & Francis Group, LLC.",

year = "2016",

month = aug,

day = "2",

doi = "10.1080/2162402X.2016.1196311",

language = "English (US)",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "8",

}

TY - JOUR

T1 - Improving vaccine efficacy against malignant glioma

AU - Ladomersky, Erik

AU - Genet, Matthew

AU - Zhai, Lijie

AU - Gritsina, Galina

AU - Lauing, Kristen L.

AU - Lulla, Rishi R.

AU - Fangusaro, Jason

AU - Lenzen, Alicia

AU - Kumthekar, Priya

AU - Raizer, Jeffrey J.

AU - Binder, David C.

AU - James, C. David

AU - Wainwright, Derek A.

PY - 2016/8/2

Y1 - 2016/8/2

N2 - The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

AB - The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival of 14.6 mo. In children, malignant glioma accounts for 20% of primary CNS tumors with a median survival of less than 1 y. Here, we discuss vaccine treatment for children diagnosed with malignant glioma, through targeting EphA2, IL-13Rα2 and/or histone H3 K27M, while in adults, treatments with RINTEGA, Prophage Series G-100 and dendritic cells are explored. We conclude by proposing new strategies that are built on current vaccine technologies and improved upon with novel combinatorial approaches.

KW - Cancer immunity

KW - Dendritic cell vaccine

KW - HSPPC-96

KW - Immunosuppression

KW - Rindopepimut

KW - cancer vaccines

KW - glioma

KW - pediatric glioma

UR - http://www.scopus.com/inward/record.url?scp=84982806196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982806196&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1196311

DO - 10.1080/2162402X.2016.1196311

M3 - Review article

C2 - 27622066

AN - SCOPUS:84982806196

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 8

M1 - e1196311

ER -

Improving vaccine efficacy against malignant glioma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this